AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31015317 — intervention group
Group type: COMPARATOR
Intervention: Oncologist practice duration
Number of subjects: 581
Study 31015317 — intervention group
Group type: COMPARATOR
Intervention: Patient ethnicity
Number of subjects: 581
Study 31015317 — intervention group
Group type: COMPARATOR
Intervention: Cancer type
Number of subjects: 581
Study 31015317 — intervention group
Group type: COMPARATOR
Intervention: Caregiver ethnicity
Number of subjects: 581
Study 31015317 — intervention group
Group type: COMPARATOR
Intervention: Caregiver physical health
Number of subjects: 581
Study 31015317 — intervention group
Group type: COMPARATOR
Intervention: Caregiver income and anxiety
Number of subjects: 581
Study 30059552 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise training for 16 weeks
Number of subjects: 134
Study 30059552 — intervention group
Group type: COMPARATOR
Intervention: Control group (original exercise mode unchanged)
Number of subjects: 134
Study 30059552 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise training
Number of subjects: 134
Study 26998485 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser plus topical application of Botulinum Toxin Type A (BTX‐A)
Number of subjects: 20
Study 26998485 — intervention group
Group type: COMPARATOR
Intervention: Fractional CO2 plus saline solution
Number of subjects: 20
Study 26998485 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (BTX‐A and saline solution)
Number of subjects: 20
Study 24517309 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass (Bypass)
Number of subjects: 0
Study 24517309 — intervention group
Group type: COMPARATOR
Intervention: Gastric band (Band)
Number of subjects: 0
Study 24517309 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 0
Study 22971260 — intervention group
Group type: EXPERIMENTAL
Intervention: Trainer for Kids™
Number of subjects: 54
Study 22971260 — intervention group
Group type: COMPARATOR
Intervention: modified Activator
Number of subjects: 54
Study 20176212 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration
Number of subjects: 65
Study 20176212 — intervention group
Group type: COMPARATOR
Intervention: Sham (circulation without an interposed filter)
Number of subjects: 65
Study 17413119 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.5 g P. ovata husk/d
Number of subjects: 28
Study 17413119 — intervention group
Group type: COMPARATOR
Intervention: 10.5 g P. ovata seeds/d
Number of subjects: 28
Study 16229653 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral fluorescence imaging combined with texture analysis and Fisher linear discrimination (FLD)
Number of subjects: 0
Study 16229653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross validation of the training set
Number of subjects: 0
Study 16229653 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast feature from co-occurrence matrices
Number of subjects: 0
Study 16229653 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood average features of autofluorescence and Pp IX fluorescence
Number of subjects: 0
Study 12882179 — intervention group
Group type: EXPERIMENTAL
Intervention: In-bed scales
Number of subjects: 2
Study 12882179 — intervention group
Group type: COMPARATOR
Intervention: Freestanding scales
Number of subjects: 2
Study 12882179 — intervention group
Group type: EXPERIMENTAL
Intervention: Weights over 1,500 g
Number of subjects: 2
Study 12882179 — intervention group
Group type: EXPERIMENTAL
Intervention: Weights < 1,500 g
Number of subjects: 2
Study 9973031 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 42
Study 9973031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 7588510 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fibre diet based on oat bran (31.9 g/day fibre)
Number of subjects: 10
Study 7588510 — intervention group
Group type: COMPARATOR
Intervention: Low-fibre diet based on wheat flour (7.8 g/day fibre)
Number of subjects: 10
Study 2372469 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopentol
Number of subjects: 12
Study 2372469 — intervention group
Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 12
Study 6999828 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketocaine compresses (1 g ketocaine in a 10% ethanol solution)
Number of subjects: 23
Study 6999828 — intervention group
Group type: COMPARATOR
Intervention: Placebo compresses (without ketocaine)
Number of subjects: 23
Study 31615445 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 270
Study 31615445 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin
Number of subjects: 270
Study 28404531 — intervention group
Group type: EXPERIMENTAL
Intervention: PC + EC group (n = 47)
Number of subjects: 214
Study 28404531 — intervention group
Group type: EXPERIMENTAL
Intervention: PC group (n = 56)
Number of subjects: 214
Study 28404531 — intervention group
Group type: EXPERIMENTAL
Intervention: EC group (n = 49)
Number of subjects: 214
Study 28404531 — intervention group
Group type: COMPARATOR
Intervention: Conventional guide group (n = 62)
Number of subjects: 214
Study 25742716 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose GH treatment (33 μg kg(‐1) day(‐1))
Number of subjects: 167
Study 25742716 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose treatment (67 μg kg(‐1) day(‐1))
Number of subjects: 167
Study 25742716 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 167
Study 24340313 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional video
Number of subjects: 133
Study 24340313 — intervention group
Group type: COMPARATOR
Intervention: Nonvideo group
Number of subjects: 133
Study 21638184 — intervention group
Group type: COMPARATOR
Intervention: Paradoxical image
Number of subjects: 61
Study 21638184 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitally flipped image (mirror-image)
Number of subjects: 61
Study 21638184 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted image
Number of subjects: 61
Study 19798097 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg daily
Number of subjects: 5665
Study 19798097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5665
Study 19798097 — intervention group
Group type: EXPERIMENTAL
Intervention: BP lowering across 10 trials
Number of subjects: 5665
Study 19798097 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics as component of therapy
Number of subjects: 5665
Study 19798097 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin system inhibitors
Number of subjects: 5665
Study 16487912 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA n‐3 and vitamin E (group B)
Number of subjects: 57
Study 16487912 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PUFA n‐3, vitamin E, gamma‐oryzanol, and niacin (group C)
Number of subjects: 57
Study 16487912 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group A)
Number of subjects: 57
Study 16117967 — intervention group
Group type: EXPERIMENTAL
Intervention: CQ + AS (4 mg/kg bodyweight daily for 3 days)
Number of subjects: 400
Study 16117967 — intervention group
Group type: COMPARATOR
Intervention: CQ (25 mg/kg bodyweight over 3 days)
Number of subjects: 400
Study 16117967 — intervention group
Group type: EXPERIMENTAL
Intervention: CQ + AS
Number of subjects: 400
Study 16117967 — intervention group
Group type: COMPARATOR
Intervention: CQ
Number of subjects: 400
Study 10836728 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine (M) 10-20 mg, od, for 24 weeks
Number of subjects: 101
Study 10836728 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (E) 10-20 mg, od, for 24 weeks
Number of subjects: 101
Study 9376779 — intervention group
Group type: EXPERIMENTAL
Intervention: bromocriptine 25 mg
Number of subjects: 366
Study 9376779 — intervention group
Group type: EXPERIMENTAL
Intervention: bromocriptine 50 mg
Number of subjects: 366
Study 9376779 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 366
Study 1317178 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.002, 0.004, and 0.007 mg/kg)
Number of subjects: 0
Study 1317178 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular glycopyrrolate (0.0044 mg/kg)
Number of subjects: 0
Study 1317178 — intervention group
Group type: COMPARATOR
Intervention: Control group (young subjects)
Number of subjects: 0
Study 3910428 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 2.5 mg i.m. before anaesthesia
Number of subjects: 112
Study 3910428 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg i.v. at the end of anaesthesia
Number of subjects: 112
Study 3910428 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 112
Study 3910428 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (i.m. or i.v.)
Number of subjects: 112
Study 3910428 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 112
Study 30201408 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg BMS-986020 (bid)
Number of subjects: 143
Study 30201408 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg BMS-986020 (qd)
Number of subjects: 143
Study 30201408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 25756560 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/d
Number of subjects: 2062
Study 25756560 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 450 mg/d
Number of subjects: 2062
Study 25756560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2062
Study 25985851 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (25,000 IU retinyl palmitate)
Number of subjects: 36
Study 25985851 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one capsule of placebo per day)
Number of subjects: 36
Study 23768842 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 puffs on arrival and 2 puffs/trial ("8+2")
Number of subjects: 23
Study 23768842 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 puffs/trial only ("0+2")
Number of subjects: 23
Study 23768842 — intervention group
Group type: COMPARATOR
Intervention: No smoking
Number of subjects: 23
Study 21600390 — intervention group
Group type: EXPERIMENTAL
Intervention: Test drug (generic Mycophenolate mofetil 500 mg)
Number of subjects: 126
Study 21600390 — intervention group
Group type: COMPARATOR
Intervention: Reference drug (branded Mycophenolate mofetil 500 mg)
Number of subjects: 126
Study 21600390 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test and reference drugs
Number of subjects: 126
Study 19713965 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg daily)
Number of subjects: 30
Study 19713965 — intervention group
Group type: COMPARATOR
Intervention: Losartan (50 mg daily)
Number of subjects: 30
Study 16449345 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 49059 (200 mg once daily)
Number of subjects: 8
Study 16449345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 15033935 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tertatolol (nonselective beta-antagonist) treatment during exercise bouts at 35% and 60% peak oxygen consumption (VO2max)
Number of subjects: 0
Study 15033935 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment during exercise bouts at 35% and 60% peak oxygen consumption (VO2max)
Number of subjects: 0
Study 11284814 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane in nitrous oxide-oxygen (2 : 1 l.min‐1)
Number of subjects: 91
Study 11284814 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl 1 microg.kg‐1 + propofol 2 mg.kg‐1 followed by nitrous oxide-oxygen (2 : 1 l.min‐1) and sevoflurane
Number of subjects: 91
Study 11284814 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl + propofol
Number of subjects: 91
Study 11284814 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 91
Study 9307536 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of prostaglandin E2 2 mg vaginal gel
Number of subjects: 995
Study 9307536 — intervention group
Group type: COMPARATOR
Intervention: Two doses of prostaglandin E2 (2 mg each, second dose after six hours if needed)
Number of subjects: 995
Study 9307536 — intervention group
Group type: COMPARATOR
Intervention: Two doses of prostaglandin E2 (2 mg each)
Number of subjects: 995
Study 8025745 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP), 500 micrograms twice per day
Number of subjects: 25
Study 8025745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 2917833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioversol
Number of subjects: 60
Study 2917833 — intervention group
Group type: COMPARATOR
Intervention: Diatrizoate
Number of subjects: 60
Study 1131804 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil plus diethylstilbestrol
Number of subjects: 0
Study 1131804 — intervention group
Group type: COMPARATOR
Intervention: diethylstilbestrol alone
Number of subjects: 0
Study 1131804 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil
Number of subjects: 0
Study 1131804 — intervention group
Group type: COMPARATOR
Intervention: CCNU
Number of subjects: 0
Study 30780190 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive azithromycin
Number of subjects: 2013
Study 30780190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2013
Study 28777127 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized vibrotactile neurofeedback training (IVNT) for ∼10 minutes each day for 2 weeks
Number of subjects: 0
Study 28777127 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized vibrotactile neurofeedback training (IVNT) combined with oral medication (20 mg cinnarizine and 40 mg dimenhydrinate, three tablets per day)
Number of subjects: 0
Study 26399571 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy (iCBT)
Number of subjects: 140
Study 26399571 — intervention group
Group type: COMPARATOR
Intervention: Weekly check-in control group
Number of subjects: 140
Study 25044795 — intervention group
Group type: EXPERIMENTAL
Intervention: Food formulations with unsaturated/saturated fat and beetroot extract
Number of subjects: 16
Study 22840549 — intervention group
Group type: EXPERIMENTAL
Intervention: ARC intervention
Number of subjects: 197
Study 22840549 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 197
Study 20377532 — intervention group
Group type: EXPERIMENTAL
Intervention: Neopuff (NP) mode with pressure dial visible
Number of subjects: 36
Study 20377532 — intervention group
Group type: COMPARATOR
Intervention: Chest wall movement (CWM) mode with pressure dial hidden
Number of subjects: 36
Study 20377532 — intervention group
Group type: EXPERIMENTAL
Intervention: Both modes (CWM and NPM)
Number of subjects: 36
Study 18656756 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic protocol using a rubber-band system (DY)
Number of subjects: 21
Study 18656756 — intervention group
Group type: COMPARATOR
Intervention: Early active thumb extension with limited flexion (AC)
Number of subjects: 21
Study 16050405 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic nephrectomy (LLDN)
Number of subjects: 50
Study 12774158 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Flow System
Number of subjects: 20
Study 12774158 — intervention group
Group type: COMPARATOR
Intervention: Babylog 8000
Number of subjects: 20
Study 10386681 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm I (A-I)
Number of subjects: 36
Study 10386681 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm II (A-II)
Number of subjects: 36
Study 9058311 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon-beta (IFN-beta) 6 million units, three times per week for 6 months
Number of subjects: 15
Study 8215790 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 1 mg/Kg/day for 5 months
Number of subjects: 11
Study 8215790 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 11
Study 8215790 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 11
Study 3525237 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate (TC) 200 mg intramuscularly every 14 days for six injections
Number of subjects: 0
Study 3525237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30184023 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional constipation
Number of subjects: 516
Study 30184023 — intervention group
Group type: EXPERIMENTAL
Intervention: Overactive bladder
Number of subjects: 516
Study 30184023 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry overactive bladder
Number of subjects: 516
Study 30184023 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet overactive bladder
Number of subjects: 516
Study 30184023 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional constipation predicting dry overactive bladder
Number of subjects: 516
Study 30184023 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life in constipated women
Number of subjects: 516
Study 30184023 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual maneuvers
Number of subjects: 516
Study 30184023 — intervention group
Group type: EXPERIMENTAL
Intervention: <3 defecations/week
Number of subjects: 516
Study 27354125 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Proton Therapy (IMPT)
Number of subjects: 81
Study 27354125 — intervention group
Group type: COMPARATOR
Intervention: Intensity Modulated Photon Therapy (IMRT)
Number of subjects: 81
Study 25547978 — intervention group
Group type: EXPERIMENTAL
Intervention: Training programme for GPs on action planning (1 hour)
Number of subjects: 49
Study 25547978 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly specific action plan enactment
Number of subjects: 49
Study 25547978 — intervention group
Group type: EXPERIMENTAL
Intervention: Plan specificity and enactment
Number of subjects: 49
Study 22863640 — intervention group
Group type: COMPARATOR
Intervention: Aged Maggi™ placebo
Number of subjects: 60
Study 22863640 — intervention group
Group type: COMPARATOR
Intervention: Fresh Maggi™ placebo
Number of subjects: 60
Study 22863640 — intervention group
Group type: COMPARATOR
Intervention: Aged artificial food coloring placebo with licorice flavor
Number of subjects: 60
Study 22863640 — intervention group
Group type: EXPERIMENTAL
Intervention: STW5
Number of subjects: 60
Study 20427546 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam (4 x 4.5 g IV/day)
Number of subjects: 127
Study 20427546 — intervention group
Group type: COMPARATOR
Intervention: Carbapenem (meropenem 3 x 1 g IV/day or imipenem 4 x 500 mg IV/day) with or without amikacin (1 g IV/day)
Number of subjects: 127
Study 18985695 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth Defects Cluster Study intervention (case-control study design with standardized methods)
Number of subjects: 0
Study 19667717 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0
Study 19667717 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib
Number of subjects: 0
Study 19667717 — intervention group
Group type: EXPERIMENTAL
Intervention: COX-2 selective inhibitors (general)
Number of subjects: 0
Study 12891643 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (16 mg per day)
Number of subjects: 0
Study 12891643 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (24 mg per day)
Number of subjects: 0
Study 12891643 — intervention group
Group type: COMPARATOR
Intervention: No cholinesterase therapy (control)
Number of subjects: 0
Study 10579145 — intervention group
Group type: EXPERIMENTAL
Intervention: Citracal (calcium citrate)
Number of subjects: 18
Study 10579145 — intervention group
Group type: EXPERIMENTAL
Intervention: Os-Cal (calcium carbonate)
Number of subjects: 18
Study 10579145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8768828 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg MK-677
Number of subjects: 9
Study 8768828 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg MK-677
Number of subjects: 9
Study 8768828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8768828 — intervention group
Group type: COMPARATOR
Intervention: All conditions
Number of subjects: 9
Study 8332270 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 15
Study 8332270 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 15
Study 8332270 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Propranolol and Nifedipine
Number of subjects: 15
Study 8332270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3298404 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir, 45 mg/kg/day by continuous intravenous infusion for 28 days
Number of subjects: 30
Study 3298404 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 30
Study 29663857 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain training program with weekly supervision (600 min playtime)
Number of subjects: 105
Study 29663857 — intervention group
Group type: COMPARATOR
Intervention: Passive intervention with supervision twice (offered after trial)
Number of subjects: 105
Study 27716229 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine (20 mL of 0.375%)
Number of subjects: 44
Study 27716229 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine with betamethasone (19 mL of 0.375% ropivacaine + 4 mg betamethasone)
Number of subjects: 44
Study 27716229 — intervention group
Group type: COMPARATOR
Intervention: Control (no betamethasone)
Number of subjects: 44
Study 24300220 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin submicron particle capsules 20 mg
Number of subjects: 203
Study 24300220 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin submicron particle capsules 40 mg
Number of subjects: 203
Study 24300220 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Number of subjects: 203
Study 24300220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 22057753 — intervention group
Group type: EXPERIMENTAL
Intervention: Limberg flap (group 1)
Number of subjects: 93
Study 22057753 — intervention group
Group type: COMPARATOR
Intervention: Tension-free primary closure (group 2)
Number of subjects: 93
Study 20195587 — intervention group
Group type: COMPARATOR
Intervention: Non-chiral method
Number of subjects: 0